



**2021 Shareholder Meeting**  
**May 18, 2021**

# FORWARD-LOOKING STATEMENTS / NON-GAAP MEASURES

This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 regarding our strategic growth drivers, among others. Forward-looking statements are neither historical facts nor assurances of future performance and are based only on our current beliefs, expectations and assumptions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: impact of COVID-19; introduction of competitive products; availability of insurance reimbursement; changes in U.S. Food and Drug Administration regulations; changes to health care policies; success of our research and development efforts; our ability to raise capital if or when needed; acceptance of and demand for new and existing products; expanded market acceptance of the FREEDOM Syringe Infusion System; our ability to obtain required governmental approvals; success in enforcing and obtaining patents; continued performance by principal suppliers; continued customer preference to work through distributors; continued service of key personnel and attracting and maintaining new personnel; the costs, duration and ultimate outcome of litigation; and general economic and business conditions. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

## **Non-GAAP Adjusted EBITDA**

Adjusted EBITDA excludes from net (loss)/income: income tax expense, depreciation and amortization, interest income, net, reorganization charges, discontinued product expense, litigation costs, manufacturing initiative expenses, and stock-based compensation.

## **Non-GAAP Measures**

This presentation includes the non-GAAP financial measure of "Adjusted EBITDA" that is not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial results. A reconciliation of our non-GAAP measure is included in an attachment to this press release.

**Shareholder Meeting**  
**Meeting Agenda – May 18, 2021**  
**Time: 9:00 am – 10:00 am**


<b>AGENDA TOPIC</b>
<b>Intro to Linda Tharby, President and CEO</b>
<b>Financial Highlights 2020</b>
<b>Financial Highlights Q1 2021</b>
<b>Strategic Growth Drivers</b>
<b>Patient Impact</b>
<b>Thank you to our Associates</b>

# New President and CEO: Linda Tharby



- Experienced global medical device industry executive
- Member of the Executive Leadership team of BD
- Global business leadership roles driving portfolio innovation and global commercialization
- Focused on pharmaceutical partnerships to address self-administration of therapies in the home.
- Enterprise change and integration experience



## 2017-2020 Net Sales (\$ in MMs)






# 2020 FINANCIAL SUMMARY (\$ in MMs)



\*Adjusted EBITDA excludes from net (loss)/income: income tax expense, depreciation and amortization, interest income, net, reorganization charges, discontinued product expense, litigation costs, manufacturing initiative expenses, and stock-based compensation


# 2021 Q1 FINANCIAL SUMMARY (\$ in MMs)




\*Adjusted EBITDA excludes from net (loss)/income: income tax expense, depreciation and amortization, interest income, net, reorganization charges, discontinued product expense, litigation costs, manufacturing initiative expenses, and stock-based compensation

# STRATEGIC GROWTH DRIVERS


## Growing US Adoption of Subcutaneous Ig Therapy\*



## International Growth





## Novel Therapies



\*Source IQVIA Data



# Patient Impact







**Thank you to our Associates for their hard work, dedication and all that they do!**

# RECONCILIATION

## Reconciliation of GAAP Net (Loss)/Income to Non-GAAP Adjusted EBITDA

	Twelve Months Ended	
	December 31,	
	2020	2019
GAAP Net (Loss)/Income	\$ (1,212,063)	\$ 564,349
Income Tax Expense	17,800	132,069
Depreciation and Amortization	418,595	340,229
Interest Income, Net	(42,395)	(80,663)
Reorganization Charges	95,700	354,926
Discontinued Product Expense	70,859	—
Litigation*	2,447,213	3,415,683
Manufacturing Initiative Expenses	246,527	230,668
Stock-Based Compensation Expense	<u>1,618,732</u>	<u>1,204,844</u>
Non-GAAP Adjusted EBITDA**	\$ <u>3,660,968</u>	\$ <u>6,162,105</u>

\*For the twelve months ended December 31, 2020, litigation consisted of a \$2.2 million non-cash, stock-based settlement expense.

\*\*Adjusted EBITDA excludes from net (loss)/income: income tax expense, depreciation and amortization, interest income, net, reorganization charges, discontinued product expense, litigation costs, manufacturing initiative expenses, and stock-based compensation

# RECONCILIATION

## Reconciliation of GAAP Net (Loss)/Income to Non-GAAP Adjusted EBITDA

	Three Months Ended		Three Months Ended	
	March 31,		December 31,	
	2021	2020	2020	
GAAP Net (Loss)/Income	\$ (1,276,138)	\$ 449,428	\$ (834,628)	
Income Tax Expense	(942,361)	141,928	(298,400)	
Depreciation and Amortization	115,473	87,224	120,794	
Interest Income, Net	(9,771)	(19,030)	(18,705)	
Reorganization Charges	969,274	—	95,700	
Discontinued Product Expense	—	109,558	(459)	
Litigation*	—	99,158	466	
Manufacturing Initiative Expenses	51,723	109,803	51,723	
	<u>734,184</u>	<u>360,968</u>	<u>607,592</u>	
Stock-Based Compensation Expense				
Non-GAAP Adjusted EBITDA**	\$ <u>(357,616)</u>	\$ <u>1,339,037</u>	\$ <u>(275,917)</u>	

\*\*Adjusted EBITDA excludes from net (loss)/income: income tax expense, depreciation and amortization, interest income, net, reorganization charges, discontinued product expense, litigation costs, manufacturing initiative expenses, and stock-based compensation



THANK YOU



*NEW LIFE, NEW  
BEGINNINGS*